Sorafenib: An emerging Targeted therapy for renal Cell and Hepatocellular Carcinomas  

Oleh:

Chan, Stephen L ; Mok, Tony SK

Jenis: Article from Bulletin/Magazine - ilmiah internasional
Dalam koleksi: Medical Progress vol. 35 no. 11 (Nov. 2008), page 547.

Ketersediaan

Perpustakaan FK Nomor Panggil: M36.K.2008.02 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Sorafenib is an oral multi-targeted kinase inhibitor which exerts both antiproliferarive and antiangiogenic effects in cancer. it has been approved for the treatment of two chemo-refractory tumours: renal cell and hepatocelular carcinomas. Sorafenib is generally well tolerated without classical toxicity of cytotoxic chemotherapy. The indication in other cancer sites are being explored in ongoing clinical trials. .....

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali